AstraZeneca strikes broad alliance for Amgen's clinical-stage inflammation portfolio
This article was originally published in Scrip
Amgen will get $50 million upfront from AstraZeneca under a collaboration agreement to jointly develop and commercialise five monoclonal antibodies from Amgen's clinical inflammation portfolio, which will allow the US biotechnology company to refocus some of its resources on earlier stage programmes.
You may also be interested in...
Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.